Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether the ability of MEK162 to antagonize MEK
activation in NS HCM patients, who usually have upstream mutations in the Ras-Raf-Mek-Erk
pathway that lead to MEK activation, would be beneficial over a 6 month treatment period in
hypertrophy regression.
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer